KRT5 is a well-established basal/myoepithelial marker in breast cancer, enriched in basal-like and triple-negative subtypes, where its upregulation has been associated with aggressive phenotypes, chemoresistance, and poorer survival outcomes [46]. This evidence concerns the gene KRT5 and breast cancer.